Combined with NNMT inhibitor and gefitinib strikingly suppressed gefitinib-resistant NSCLC cells growth, which might be a promising strategy for the treatment of patients with acquired resistance to EGFR TKI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.